0:15 Intro

3:09 Low-dose CT screening uptake in Canada

4:45 Evolution of adjuvant, neoadjuvant therapies

7:10 Reviewing CheckMate 816

10:56 Reviewing KEYNOTE-671

12:58 The impact of neoadjuvants on operability

16:15 Treatment-specific biomarkers for lung cancer

21:13 The short-term future of lung cancer therapy

24:31 Outro

Precision medicine–delivering the right drug at the right time to the right patient–is the direction in which lung cancer treatment is heading. In this episode, we talk about an exciting, emerging drug class with one of the most prominent investigators involved with its development, Dr. Jonathan Spicer at McGill University’s Thoracic Oncology Network. 

It provides a deep dive into neoadjuvant therapy for patients who have operable lung cancer, offering insight into what is currently known about response and failure rates.

Want more Lungcast? Visit us at HCPLive.com/podcasts/lungcast or www.lung.org/professional-education/lungcast